EPIX250117C10000
- 0.45
- 0.000.00%
ESSA Pharma Newsroom
When Will ESSA Pharma Inc. (NASDAQ:EPIX) Turn A Profit?
ESSA Pharma's Cash Management: A Potential Risk to Shareholder Value and Market Stability
ESSA Pharma Inc. Reports Strategic Shift Amid Losses
ESSA Pharma: Fiscal Q4 Earnings Snapshot
ESSA Pharma | 8-K: ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024
Express News | ESSA Pharma Inc: Strategic Review Expected to Involve Headcount and Other Cost Reductions
Express News | ESSA Pharma Inc: Initiated Comprehensive Process to Explore and Review a Range of Strategic Options
ESSA Pharma | 10-K: FY2024 Annual Report
Express News | ESSA Pharma Inc: Qtrly Loss per Share $0.14
Express News | ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024
Essa Pharma 4Q Loss/Shr 14c >EPIX
Press Release: ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024
Bloom Burton Downgrades ESSA Pharma(EPIX.US) to Hold Rating, Cuts Target Price to $2.25
Express News | ESSA Pharma Inc - Terminates License Agreement With British Columbia Cancer Agency and Ubc
ESSA Pharma Introduces New Executive Severance Plan
Earnings Week Ahead: CRM, DOCU, OKTA, ZS, S, MRVL, LULU, DG, and More
Express News | Tang Capital Management, LLC Reports 9.7% Stake in ESSA Pharma as of Nov 1- SEC Filing
ESSA Pharma(EPIX.US) 10% Shareholder Sells US$12.02 Million in Common Stock
$ESSA Pharma(EPIX.US)$ 10% Shareholder BIOTECH GROWTH N V sold 7.88 million shares of common stock on Nov 1, 2024 at an average price of $1.5253 for a total value of $12.02 million. This transaction
ESSA Pharma Slides As Insider Purchases Lose Another US$211k
ESSA Pharma Shares Are Trading Lower After Oppenheimer Downgraded the Stock From Outperform to Perform. Piper Sandler Downgraded Its Rating From Overweight to Neutral and Cut Its Price Target From $15 to $2.